| Overview |
| bsm-61939r-cy5-100ul |
| METAP2 Recombinant Monoclonal Antibody, Cy5 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human METAP2 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10988 |
| P50579 |
| Cytoplasm |
| Amp2; MAP2; Metap2; MNPEP; p67; p67eIF2. |
| Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz